iRhythm Technologies, Inc. IRTC
Spruce Point argues iRhythm hid FDA-flagged Zio AT defects that killed patients and faces a DOJ cover-up probe; commoditized tech and an overstated asymptomatic market imply 40-70% downside.
Thesis
Spruce Point issues a Strong Sell on iRhythm Technologies (NASDAQ: IRTC), arguing investors have become complacent about unresolved regulatory and governance risks. After a forensic review and a proprietary survey of 100 cardiologists, Spruce Point documents how multiple FDA Form 483s and a May 2023 Warning Letter exposed transmission-limit and patient-registration flaws in the Zio AT monitor, defects tied to at least two patient deaths, while recently unsealed court filings indicate the DOJ is investigating a management cover-up spanning more than a decade. The firm contends iRhythm's core technology is commoditized, the touted 27-million-patient asymptomatic market is a mirage given smartwatch substitutes and cardiologist skepticism, and CEO Quentin Blackford has repeatedly downplayed FDA findings while insiders sold roughly $190 million of stock since 2018. Applying testing-services multiples of 2x-4x 2026E revenue, Spruce Point derives a $43-$94 price target, implying 40%-70% downside from $160.58.
SCQA
iRhythm dominates long-term ambulatory cardiac monitoring with ~70% share of the Zio patch franchise, trades at a $5.4B market cap and 6.7x 2026E revenue, and is pitched to investors as a high-growth medtech leader with a large asymptomatic expansion opportunity.
Multiple FDA Form 483s and a May 2023 Warning Letter revealed Zio AT transmission and registration defects linked to two patient deaths; recently unsealed filings suggest the DOJ is investigating a management cover-up — yet shares have rallied 141% over the past year.
Sell IRTC: products are commoditized, the asymptomatic growth story is flawed, CEO Blackford's regulatory record should not be survivable, and the company should be valued like a testing-services firm rather than an innovative medical-device maker.
Applying a 2x-4x revenue multiple to 2026E consensus of $828-$847M yields a price target of $43-$94 per share, representing roughly 40% to 70% downside from the $160.58 current price.
The three reasons
- 1
FDA found Zio AT defects linked to at least two patient deaths; DOJ probing management cover-up
- 2
Commoditized product, overstated asymptomatic market, and smartwatch substitutes threaten growth
- 3
Testing-services 2x-4x multiple on 2026E revenue implies $43-$94 target, 40-70% downside
Primary demands
- Sell iRhythm shares (Strong Sell opinion) given unresolved FDA and DOJ regulatory overhang
- Recognize CEO Quentin Blackford as an unreliable messenger; regulatory failures should not be a 'survivable event' for him
- Re-rate iRhythm to a testing-services multiple (2x-4x 2026E revenue) rather than premium medical-device multiple
- Board should stop rewarding management with remediation-linked incentive compensation
KPIs cited
Pattern membership
Precedents cited
- Spruce Point short campaign: Stryker (NYSE: SYK, 2022) — shares down 30% post-report
- Spruce Point short campaign: Heska (Nasdaq: HSKA, 2021) — acquired 48% below unaffected price
- Spruce Point short campaign: Progyny (Nasdaq: PGNY, 2023) — shares -54% in 2024
- Spruce Point short campaign: Procept BioRobotics (Nasdaq: PRCT, 2025) — shares -33% over three months
- Apple disrupting the hearing-aid market (analogy for smartwatches disrupting cardiac monitoring)
- NuVasive 2013 FDA warning letter and 2015 $13.5M DOJ settlement (Blackford was CFO)
- Dexcom playbook criticism (Spruce Point's March 2019 Dexcom short, where Blackford was COO/CFO)
Composition what's on the 101 slides
Slide gallery ·
Notes
101-page Spruce Point short report on iRhythm Technologies (IRTC), dated 8/18/2025. Cover uses a memorable AI-style cartoon of a cardiologist in a patient room with a speech bubble ('I have minimal concerns, let's go with the watch monitor') under the tagline 'Investor Complacency is Off the Charts' — unusual editorial touch for a short deck. Firm-authored (no individual signatory). Heavy use of 'Pitch vs Reality' CEO-quote-contradiction tables (Blackford on Zio AT quality, Japan reimbursement, MCT product, CCT separation) — pages 17 and 89 are the archetypes. Page 93 shows a striking 2022-vs-2024 Code of Conduct word-frequency comparison ('criminal' 10 -> 0, 'fraud/fraudulent' 15 -> 0) as evidence of management softening governance. Page 4 showcases Spruce Point's own track record (Stryker/Heska/Progyny/Procept) as implicit precedent and credibility play — a common short-seller opener. Valuation is pure multiple-comparison (2x-4x revenue on testing-services comps) with no SOTP or DCF. Stake not disclosed beyond a boilerplate short-position statement. Campaign_phase set to initial_thesis as this appears to be Spruce Point's first public deck on IRTC.